Compare Invesco Ltd. (IVZ) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Tenet Healthcare Corporation — how do they compare? Invesco Ltd. trades at $31.5 (market cap $13.85B), while Tenet Healthcare Corporation trades at $264 (market cap $20.89B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Invesco Ltd. pays a 2.74% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| IVZ | THC | |
|---|---|---|
Market Cap | $13.85B | $20.89B |
Sector | Financials | Health |
52-Week High | $32.01 | $262.63 |
52-Week Low | $20.67 | $161.37 |
Enterprise Value | $24.01B | $31.97B |
Dividend Yield | 2.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $31.74, near its 52-week high, with a bullish technical signal supported by moving averages. The company reported mixed quarterly earnings but maintains strong operating cash flow of $1.53 billion for 2025. Recent news highlights record assets under management and positive analyst coverage, though profitability metrics show net income margin at -0.93%.
The outlook remains cautiously optimistic with a consensus price target of $32.50, offering modest upside. Key risks include volatile earnings and expense pressures, while institutional interest and dividend payments provide support. Investors should weigh solid cash generation against margin challenges.
Tenet Healthcare (THC) trades at $260.67, up 0.28% today, with strong technical momentum including a golden cross pattern and bullish moving average alignment. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.12 versus $4.26 forecast, maintaining a three-quarter earnings beat streak. Valuation metrics remain attractive with P/E of 10.03 and EV/EBITDA of 5.73, while profitability metrics show exceptional ROE of 53.31% and net margin of 9.9%.
The investment outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target representing 8% upside. Key risks include policy headwinds in ACA exchanges and hospital segment challenges, though strong ambulatory growth provides offset. The stock presents a compelling value-growth combination with momentum characteristics, supported by institutional accumulation and positive earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
